Navigation Links
Microfluidic technology reveals potential biomarker for early pancreatic cancer
Date:4/29/2014

ANN ARBOR, Mich. Cancer cells are on the move in the bloodstream in the very early stage of pancreatic cancer, and can be detected before cancer is diagnosed, according to research by the University of Michigan Health System.

In a study of 51 patients, researchers used a state-of-the art microfluidic device to capture circulating pancreas epithelial cells in 33 percent of patients with early pancreatic lesions and no clinical diagnosis of cancer.

The findings, published in Gastroenterology, suggest that circulating pancreas cells (CPCs) seed the bloodstream before tumors can be detected using current clinical tests such as CT and MRI scans. The data suggest that the detection of pancreas cells in the blood may be an early sign of cancer.

"While there is much work that still needs to be done, there is great potential for using this technology to identify who is most at risk for developing pancreatic cancer," says lead author Andrew Rhim, M.D., an assistant professor of internal medicine at the U-M Health System and gastroenterologist at the U-M Comprehensive Cancer Center's Multidisciplinary Pancreatic Cancer Clinic.

One reason the outlook for pancreatic cancer is poor is that very few of the cancers are found early. Patients usually have no symptoms until the cancer has spread to other organs. There are no blood tests to find early cancers of the pancreas.

It is thought that cancer cells seed the bloodstream late in cancer progression, when large tumors are present. But based on studies in animal models of pancreatic cancer, U-M researchers and colleagues theorized that dissemination happens before we tumors can be detected.

They studied three groups of patients: those who were cancer-free, those diagnosed with precancerous cystic lesions, and patients with pancreatic cancer. Researchers captured circulating epithelial cells in 73 percent of patients with cancer. None of the 19 cancer-free patients without lesions had these cells in their bloodstream.

"Studies are underway to interrogate the genomic signature of circulating pancreas cells from patients with precancerous cystic lesions," says Rhim.

"If these cells represent the earliest forms of cancer, we predict they would possess many of the genetic anomalies we typically see in pancreas tumors."


'/>"/>

Contact: Shantell M. Kirkendoll
smkirk@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert  

Related medicine news :

1. Microfluidics Market to Grow at a CAGR of 17.6% to 2018 Forecasts in New Research Report at RnRMarketResearch.com
2. Microfluidics Market Worth $3.5 Billion by 2018
3. Mechanical tissue resuscitation technology shows promise
4. New study identifies how information technology is used to solve global health challenges
5. Power generation technology based on piezoelectric nanocomposite materials developed by KAIST
6. Simulation technology allows users to safely practice phacoemulsification cataract surgery
7. The Casey Group's Sales Navigator Wins 2012 Best Mobility App in the New Jersey Technology Council's Mobile Application Competition
8. Swanson Health Products Introduces a New Alkalizing Drink Mix, Swanson® pH Balance Alka-Tone with Alka-Plex™ Technology
9. Miami Children’s Hospital Performs First Nerve Repair Surgery Using Avance® Nerve Graft Technology
10. FDA Approves SonixGPS Needle Guidance Technology for Vascular Access Procedures
11. IVR Technology Group Named Platimum VAR by TSYS
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Microfluidic technology reveals potential biomarker for early pancreatic cancer
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American Respiratory ... testing company, is now able to perform sophisticated lung assessments in ... Medical Technologies , Inc. Patients are no longer ... to ndd,s EasyOne PRO ® , ARL patients like Jeanne R. ... testing done in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
Breaking Medicine Technology: